NASDAQ: ATRI | Healthcare / Medical Devices & Instruments / USA |
409.70 | +1.65 | +0.40% | Vol 11.00K | 1Y Perf -28.91% |
Oct 3rd, 2023 16:00 DELAYED |
BID | 375.88 | ASK | 441.24 | ||
Open | 419.54 | Previous Close | 408.05 | ||
Pre-Market | - | After-Market | 409.70 | ||
- - | - -% |
Target Price | 300.00 | Analyst Rating | — 0.00 | |
Potential % | -26.78 | Finscreener Ranking | ★★★★+ 57.27 | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★★+ 59.26 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★+ 60.65 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | ★★★+ 48.48 | |
Price Range Ratio 52W % | 3.39 | Earnings Rating | Buy | |
Market Cap | 720.93M | Earnings Date | 14th Nov 2023 | |
Alpha | -0.01 | Standard Deviation | 0.08 | |
Beta | 0.51 |
Today's Price Range 405.73433.15 | 52W Range 399.30705.74 | 5 Year PE Ratio Range 26.2051.40 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 1.71% | ||
1 Month | -13.18% | ||
3 Months | -28.13% | ||
6 Months | -36.03% | ||
1 Year | -28.91% | ||
3 Years | -32.35% | ||
5 Years | -39.11% | ||
10 Years | 63.26% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 9.47 | |||
ROE last 12 Months | 15.51 | |||
ROA (5Y Avg) | 7.43 | |||
ROA last 12 Months | 13.93 | |||
ROC (5Y Avg) | 13.88 | |||
ROC last 12 Months | 14.06 | |||
Return on invested Capital Q | 3.52 | |||
Return on invested Capital Y | 3.30 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 7.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
30.00 | ||||
4.17 | ||||
7.44 | ||||
26.80 | ||||
-142.80 | ||||
21.64 | ||||
4.37 | ||||
138.93 | ||||
980.33M | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.90 | ||||
7.40 | ||||
- | ||||
- | ||||
- | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
41.50 | ||||
21.40 | ||||
29.00 | ||||
26.40 | ||||
18.97 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
140.65M | ||||
79.35 | ||||
2.29 | ||||
2.20 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.46 | ||||
8.60 | ||||
11.38 | ||||
12.60 | ||||
Payout ratio | 40.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2024 | - | 3.73 | - |
Q01 2023 | - | 1.98 | - |
Q04 2022 | - | 4.70 | - |
Q03 2022 | - | 4.94 | - |
Q02 2022 | - | 5.20 | - |
Q01 2022 | - | 4.71 | - |
Q04 2021 | - | 4.50 | - |
Q03 2021 | - | 4.58 | - |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 14th Nov 2023 |
Estimated EPS Next Report | - |
Estimates Count | - |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 11.00K |
Shares Outstanding | 1.76K |
Shares Float | 1.36M |
Trades Count | 934 |
Dollar Volume | 4.61M |
Avg. Volume | 4.19K |
Avg. Weekly Volume | 5.29K |
Avg. Monthly Volume | 4.05K |
Avg. Quarterly Volume | 3.24K |
Atrion Corporation (NASDAQ: ATRI) stock closed at 408.05 per share at the end of the most recent trading day (a -1.24% change compared to the prior day closing price) with a volume of 2.45K shares and market capitalization of 720.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 616 people. Atrion Corporation CEO is David A. Battat.
The one-year performance of Atrion Corporation stock is -28.91%, while year-to-date (YTD) performance is -27.06%. ATRI stock has a five-year performance of -39.11%. Its 52-week range is between 399.3 and 705.74, which gives ATRI stock a 52-week price range ratio of 3.39%
Atrion Corporation currently has a PE ratio of 30.00, a price-to-book (PB) ratio of 4.17, a price-to-sale (PS) ratio of 7.44, a price to cashflow ratio of 26.80, a PEG ratio of -, a ROA of 13.93%, a ROC of 14.06% and a ROE of 15.51%. The company’s profit margin is 18.97%, its EBITDA margin is 29.00%, and its revenue ttm is $140.65 Million , which makes it $79.35 revenue per share.
Of the last four earnings reports from Atrion Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Atrion Corporation’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Atrion Corporation is — (0), with a target price of $300, which is -26.78% compared to the current price. The earnings rating for Atrion Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Atrion Corporation has a dividend yield of 1.46% with a dividend per share of $8.60 and a payout ratio of 40.00%.
Atrion Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.23, ATR14 : 12.77, CCI20 : -105.67, Chaikin Money Flow : -0.07, MACD : -20.13, Money Flow Index : 44.16, ROC : -9.44, RSI : 32.38, STOCH (14,3) : 12.36, STOCH RSI : 0.66, UO : 39.67, Williams %R : -87.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Atrion Corporation in the last 12-months were: Athey Preston (Buy at a value of $104 670), Battat David A (Option Exercise at a value of $0), BATTAT EMILE A (Option Exercise at a value of $0), Jeffery Strickland (Option Excercise at a value of $0), Jeffery Strickland (Sold 1 000 shares of value $675 000 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | - | - | Strong Sell |
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
CEO: David A. Battat
Telephone: +1 972 390-9800
Address: One Allentown Parkway, Allen 75002, TX, US
Number of employees: 616
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.